

Financial Statement 2022-2023
Third Quarter
(Unaudited)



SQUARE Pharmaceuticals Ltd.
(Consolidated and Separate)



SQUARE Pharmaceuticals Ltd.

And its subsidiaries

Consolidated Statement of Financial Position (Unaudited) As at March 31, 2023

Particulars	Notes	31-Mar-23	30-Jun-22
		Taka	Taka
ASSETS			
Non-Current Assets:			
		50,233,596,854	47,641,000,829
Property, Plant and Equipment	2	27,815,020,306	27,182,672,428
Investment in Associates	3	12,245,630,586	11,105,181,456
Investment in Marketable Securities	4	4,432,755,045	4,346,770,865
Long Term Investment - Others	5	5,740,190,917	5,006,376,080
Current Assets:			
		67,146,213,238	62,347,727,888
Inventories	6	11,264,559,965	8,214,111,144
Trade and Other Receivables	7	3,792,674,332	3,395,080,462
Advances, Deposits and Prepayments	8	1,598,098,720	1,776,037,947
Cash and Cash Equivalents	9	50,490,880,222	48,962,498,336
TOTAL ASSETS		117,379,810,092	109,988,728,717
EQUITY AND LIABILITIES			
Shareholders' Equity:			
		109,328,487,006	103,452,979,750
Share Capital		8,864,510,100	8,864,510,100
Share Premium		2,035,465,000	2,035,465,000
General Reserve		105,878,200	105,878,200
Fair Value Reserve	10	643,775,757	830,615,740
Translation Reserve	11	26,321,808	8,998,071
Retained Earnings	12	97,652,536,141	91,607,512,639
Non Controlling Interests	13	252,453	469,632
TOTAL EQUITY		109,328,739,459	103,453,449,383
Non-Current Liabilities:			
		2,621,000,196	2,873,450,552
Long Term Loan	14	1,471,952,125	1,694,710,262
Deferred Tax Liabilities	15	1,149,048,071	1,178,740,290
Current Liabilities:			
		5,430,070,437	3,661,828,783
Long Term Loan - Current Portion	16	440,950,067	200,000,000
Trade Payables		1,100,027,485	636,003,309
Other Payables	17	2,222,749,171	1,603,882,464
Current Tax Liabilities	18	1,361,966,072	911,504,873
Accrued Expenses	19	180,130,518	180,802,107
Unclaimed Dividend		124,247,124	129,636,029
TOTAL LIABILITIES		8,051,070,633	6,535,279,335
TOTAL EQUITY AND LIABILITIES		117,379,810,092	109,988,728,717
Net Assets Value (NAV) per Share	30	123.33	116.70

Sd/-
Samuel S Chowdhury
Chairman

Sd/-
Ratna Patra
Vice Chairman

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Muhammad Zahangir Alam
Chief Financial Officer

Sd/-
Khandaker Habibuzzaman
Company Secretary



SQUARE Pharmaceuticals Ltd.

And its subsidiaries

Consolidated Statement of Profit or Loss and Other Comprehensive Income (Unaudited) For the 3rd Quarter ended March 31, 2023

Particulars	Notes	Nine Months Results		3rd Quarter Results	
		Jul'22 - Mar'23	Jul'21 - Mar'22	Jan'23 - Mar'23	Jan'22 - Mar'22
		Taka	Taka	Taka	Taka
Gross Revenue	20	55,858,392,389	50,731,198,331	18,329,969,468	16,881,356,230
Less: Value Added Tax		7,714,322,621	7,008,958,984	2,442,606,903	2,231,354,699
Net Revenue		48,144,069,768	43,722,239,347	15,887,362,566	14,650,001,531
Cost of Goods Sold	21	(23,604,696,522)	(20,998,326,875)	(8,214,266,551)	(7,125,580,503)
Gross Profit		24,539,373,246	22,723,912,472	7,673,096,015	7,524,421,028
Operating Expenses:		(9,763,683,711)	(8,116,818,996)	(3,442,282,429)	(2,793,464,982)
Selling and Distribution Expenses	22	(8,607,757,558)	(7,163,852,051)	(3,046,114,879)	(2,443,421,964)
Administrative Expenses	23	(1,080,003,166)	(952,941,545)	(354,002,820)	(350,040,527)
Finance Cost	24	(75,922,988)	(25,400)	(42,164,730)	(2,491)
Other Operating Income	25	740,675,243	134,895,879	193,771,112	45,548,721
Profit from Operations		15,516,364,778	14,741,989,356	4,424,584,697	4,776,504,768
Other Income	26	2,867,108,338	2,447,989,855	975,477,026	763,923,295
Profit before WPPF & WF		18,383,473,116	17,189,979,211	5,400,061,722	5,540,428,063
Allocation for WPPF & WF		(914,211,268)	(828,569,909)	(290,584,973)	(273,291,736)
Profit before Tax		17,469,261,847	16,361,409,303	5,109,476,749	5,267,136,327
Income Tax Expenses:	27	(4,020,422,924)	(3,607,026,788)	(1,276,261,168)	(1,198,979,191)
Current Tax (Expense)		(4,029,355,145)	(3,638,128,933)	(1,272,406,925)	(1,202,391,154)
Deferred Tax (Expense) / Income		8,932,221	31,102,145	(3,854,243)	3,411,963
Profit after Tax		13,448,838,924	12,754,382,515	3,833,215,581	4,068,157,136
Profit from Associate Undertakings	28	1,460,477,500	1,456,151,292	449,656,818	501,376,788
Net Profit after Tax		14,909,316,424	14,210,533,807	4,282,872,399	4,569,533,924
Other Comprehensive Income:					
Unrealised Gain/(Loss) on FVOCI Financial Assets (Net of Tax)	29	(186,839,983)	(107,704,305)	37,335,775	(91,766,782)
Foreign Operation Translation Gain/(Loss)	11	17,323,737	(47,159,219)	(64,926,590)	(11,946,170)
Other Comprehensive Income (Net of Tax)		(169,516,246)	(154,863,524)	(27,590,814)	(103,712,952)
Total Comprehensive Income for the Period		14,739,800,178	14,055,670,283	4,255,281,584	4,465,820,973
Net Profit Attributable to:					
Equity Holders of the Company		14,909,533,603	14,210,545,093	4,283,040,429	4,569,541,067
Non Controlling Interest		(217,180)	(11,286)	(168,030)	(7,143)
		14,909,316,424	14,210,533,807	4,282,872,399	4,569,533,924
Total Comprehensive Income Attributable to:					
Equity Holders of the Company		14,740,017,357	14,055,681,569	4,255,449,614	4,465,828,115
Non Controlling Interest		(217,180)	(11,286)	(168,030)	(7,143)
		14,739,800,178	14,055,670,283	4,255,281,584	4,465,820,973
Earnings Per Share (EPS)	31	16.82	16.03	4.83	5.15

Sd/-
Samuel S Chowdhury
Chairman

Sd/-
Ratna Patra
Vice Chairman

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Muhammad Zahangir Alam
Chief Financial Officer

Sd/-
Khandaker Habibuzzaman
Company Secretary



SQUARE Pharmaceuticals Ltd.

And its subsidiaries

Consolidated Statement of Changes in Equity (Unaudited) For the 3rd Quarter ended March 31, 2023

(July 2022 - March 2023)

Particulars	Share Capital	Share Premium	General Reserve	Fair Value Reserve	Translation Reserve	Retained Earnings	Non Controlling Interests	Total
	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka
As At 30 June 2022	8,864,510,100	2,035,465,000	105,878,200	830,615,740	8,998,071	91,607,512,639	469,632	103,453,449,383
Net Profit after Tax	-	-	-	-	-	14,909,533,603	(217,180)	14,909,316,423
Other Comprehensive Income (Net of Tax)	-	-	-	(186,839,983)	17,323,737	-	-	(169,516,246)
Cash Dividend for the year 2021-2022	-	-	-	-	-	(8,864,510,100)	-	(8,864,510,100)
As At 31 March 2023	8,864,510,100	2,035,465,000	105,878,200	643,775,757	26,321,808	97,652,536,141	252,453	109,328,739,459

Consolidated Statement of Changes in Equity (Unaudited) For the 3rd Quarter ended March 31, 2022

(July 2021 - March 2022)

Particulars	Share Capital	Share Premium	General Reserve	Fair Value Reserve	Translation Reserve	Retained Earnings	Non Controlling Interests	Total
	Taka	Taka	Taka	Taka	Taka	Taka	Taka	Taka
As At 30 June 2021	8,864,510,100	2,035,465,000	105,878,200	1,139,626,144	(285,055)	78,749,448,779	500,000	90,895,143,168
Net Profit after Tax	-	-	-	-	-	14,210,545,093	(11,286)	14,210,533,807
Other Comprehensive Income (Net of Tax)	-	-	-	(107,704,305)	(47,159,219)	-	-	(154,863,524)
Cash Dividend for the year 2020-2021	-	-	-	-	-	(5,318,706,060)	-	(5,318,706,060)
As At 31 March 2022	8,864,510,100	2,035,465,000	105,878,200	1,031,921,839	(47,444,274)	87,641,287,812	488,714	99,632,107,391

Sd/-
Samuel S Chowdhury
Chairman

Sd/-
Ratna Patra
Vice Chairman

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Muhammad Zahangir Alam
Chief Financial Officer

Sd/-
Khandaker Habibuzzaman
Company Secretary



SQUARE Pharmaceuticals Ltd.

And its subsidiaries

Consolidated Statement of Cash flows (Unaudited) For the 3rd Quarter ended March 31, 2023

Particulars	Notes	Jul'22 - Mar'23	Jul'21 - Mar'22
		Taka	Taka
Cash Flows from Operating Activities:			
Receipts from Customers		55,453,759,527	51,025,133,340
Receipts from Others		164,892,474	62,455,245
Payments to Suppliers		(20,006,887,989)	(15,283,010,182)
Payments for Manufacturing and Operating Expenses		(14,255,897,205)	(12,071,116,400)
Payment of Value Added Tax		(7,714,322,621)	(7,008,958,984)
Cash Generated from Operations		13,641,544,186	16,724,503,019
Interest Paid		(42,965,437)	(25,400)
Payment of Income Tax		(3,362,259,719)	(3,525,834,211)
Payment of WPPF		(582,622,183)	(937,796,627)
Others		53,613,923	32,001,264
Net Cash Generated from Operating Activities		9,707,310,769	12,292,848,045
Cash Flows from Investing Activities:			
Acquisition of Property, Plant and Equipment		(2,330,054,327)	(5,192,540,474)
Long Term Investment		(733,814,837)	(1,514,452,723)
Investment in Marketable Securities		(209,205,845)	412,359,792
Interest Received		2,799,475,827	2,370,971,511
Dividend Received		476,536,941	241,759,084
Net Cash Used in Investing Activities		2,937,760	(3,681,902,811)
Cash Flows from Financing Activities:			
Payment of Dividend		(8,793,165,079)	(5,294,296,721)
Unclaimed Dividend transferred to Capital Market Stabilisation Fund		-	(262,503,350)
Term Loan Received		18,191,930	1,721,681,855
Net Cash Used in Financing Activities		(8,774,973,149)	(3,835,118,216)
Net Increase/(Decrease) in Cash and Cash Equivalents		935,275,380	4,775,827,019
Net Effect of Foreign Exchange Fluctuations on Cash and Cash Equivalent		593,106,506	25,281,415
Cash and Cash Equivalents as at 30 June 2022		48,962,498,336	43,364,039,004
Cash and Cash Equivalents as at 31 March 2023		50,490,880,222	48,165,147,438
Net Operating Cash Flow (NOCF) per Share	32	10.95	13.87

Sd/-
Samuel S Chowdhury
Chairman

Sd/-
Ratna Patra
Vice Chairman

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Muhammad Zahangir Alam
Chief Financial Officer

Sd/-
Khandaker Habibuzzaman
Company Secretary



SQUARE Pharmaceuticals Ltd.

And its subsidiaries

Notes to the Consolidated Interim Financial Statements (Unaudited) For the 3rd Quarter Ended 31 March 2023

1. Basis of Preparation of the Consolidated Interim Financial Statements:

These Financial Statements ('They') are the unaudited consolidated Interim Financial Statements (here after 'the Interim Financial Statements') of Square Pharmaceuticals Ltd., a company incorporated in Bangladesh under Companies Act, 1913; Square Pharmaceuticals Kenya EPZ Ltd., incorporated in Kenya under Companies Act, 2015, Kenya, and Square Lifesciences Ltd., incorporated in Bangladesh under Companies Act, 1994 for the 3rd Quarter Ended on March 31, 2023 (here after 'the interim period'). They are prepared in accordance with the International Accounting Standard (IAS) 34 - 'Interim Financial Reporting'. These financial statements should be read in conjunction with the Annual Financial Statements as of June 30, 2022, as they provide an update of previously reported information.

The accounting policies and presentation used are consistent with those used in the Annual Financials, except where noted below, Where necessary, the comparative figures have been reclassified or extended from the previously reported Interim Financial Statements to take into account any presentational changes made in the Annual Financial Statements or in these Interim Financial Statements.

The preparation of the financial statements requires management to make estimates and assumptions that affect the reported amounts of revenue, expenses, assets, liabilities and disclosure of contingent liabilities at the date of the Interim Financial Statement. If in the future such estimates and assumptions, which are based on management's best judgement at the date of the Interim Financial Statements, deviate from the actual circumstances, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

The management understands that the business is growing every year which reflects that the assets are performing according to the intention of procurement. The management also assess that the discounted future cash flow from the operation of the assets would be positive if the assets are disposed at the date of financial reporting. But at present, the management has no intention to dispose these assets. Therefore, it is not necessary to record any impairment for the period as per the provisions of IAS-36.

The company operates in industries where significant seasonal or cyclical variations in total sales are not experienced during the reporting period.

The company has no reportable operating segments as per IFRS-8.

Figures have been rounded off to the nearest Taka.

Foreign Currency Translation:

The Financials of Square Pharmaceuticals Kenya EPZ Ltd. have been drawn in KHS (Kenyan Shilling) as reporting currency in Kenya. These Financials are converted in BDT to Consolidate with the Financials of Square Pharmaceuticals Ltd. as the parent company.

1 KES = 0.809 BDT as on 31.03.2023

2. Consolidated Property, Plant and Equipment: Tk. 27,815,020,306

Cost:

	31-Mar-23	30-Jun-22
Opening Balance	43,719,669,981	41,570,311,740
Addition during the Period/Year	5,774,335,623	2,408,952,601
	49,494,005,604	43,979,264,341
Sales/Transfer during the Period/Year	-	(259,594,360)
Closing Balance	Tk. 49,494,005,604	43,719,669,981

Accumulated Depreciation:

Opening Balance	23,446,178,095	21,793,391,083
Charged during the Period/Year	1,667,559,300	1,835,173,760
	25,113,737,395	23,628,564,843
Sales/Transfer during the Period/Year	-	(182,386,748)
Closing Balance	Tk. 25,113,737,395	23,446,178,095

Net Book Value as at 31 March 2023

Consolidated Property, Plant and Equipment in Transit (Note - 2.1)	573,618,663	521,564,753
Consolidated Building under Construction (Note - 2.2)	1,328,363,271	2,066,237,283
Consolidated Capital Work in Progress (Note - 2.3)	1,532,770,163	4,321,378,506
Written Down Value	Tk. 27,815,020,306	27,182,672,428

2.1 Consolidated Property, Plant and Equipment in Transit: Tk. 573,618,663

Opening Balance	521,564,753	646,809,312
Addition during the Period/Year	632,943,660	1,271,900,734
	1,154,508,413	1,918,710,046
Transfer during the Period/Year	(580,889,750)	(1,397,145,293)
Closing Balance	Tk. 573,618,663	521,564,753

2.2 Consolidated Building under Construction: Tk. 1,328,363,271

Opening Balance	2,066,237,283	1,345,864,835
Addition during the Period/Year	516,448,341	1,280,219,869
	2,582,685,624	2,626,084,704
Transfer during the Period/Year	(1,254,322,353)	(559,847,421)
Closing Balance	Tk. 1,328,363,271	2,066,237,283

	31-Mar-23	30-Jun-22
2.3 Consolidated Capital Work in Progress: Tk. 1,532,770,163		
Opening Balance	4,321,378,506	1,114,508,832
Addition during the Period/Year	472,419,660	3,158,712,287
Interest during Construction Period	-	48,157,387
	<u>4,793,798,166</u>	<u>4,321,378,506</u>
Transfer during the Period/Year	<u>(3,261,028,003)</u>	<u>-</u>
Closing Balance	<u>Tk. 1,532,770,163</u>	<u>4,321,378,506</u>

3. Consolidated Investment in Associates: Tk. 12,245,630,586		
Opening Balance	11,105,181,456	9,277,247,222
Add: Profit/(Loss) during the Period/Year (Note - 27)	1,460,477,500	2,010,807,588
Less: Dividend received during the Period/Year	<u>(320,028,370)</u>	<u>(182,873,354)</u>
Closing Balance	<u>Tk. 12,245,630,586</u>	<u>11,105,181,456</u>

List of Associate Undertakings (As per IAS-28):

Name of Associates	Country of Incorporation	Proportion of Ownership Interest
Square Textiles Ltd.	Bangladesh	46.36%
Square Fashions Ltd.	Bangladesh	48.63%
Square Hospitals Ltd.	Bangladesh	49.94%

Voting power is not different with proportion of ownership interest. The group is using equity method of accounting for investment in preparing consolidated financial statements.

Particulars	2022-2023 (Jul'22-Mar'23)		2021-2022 (Jul'21-Jun'22)	
	Cost	Market Value	Cost	Market Value
	Opening Balance	3,423,864,487	4,346,770,865	3,307,788,552
Addition during the Period/Year	341,626,411	218,404,746	627,115,212	562,894,183
Sold during the Period/Year	<u>(48,042,250)</u>	<u>(132,420,566)</u>	<u>(511,039,277)</u>	<u>(840,455,024)</u>
Closing Balance	<u>Tk. 3,717,448,648</u>	<u>4,432,755,045</u>	<u>3,423,864,487</u>	<u>4,346,770,865</u>

5. Consolidated Long Term Investment - Others: Tk. 5,740,190,917		
Ordinary Shares (Unquoted):	27,694,430	27,694,430
(a) United Hospital Ltd. (120,000 Ordinary Shares of Tk.100/- each)	12,000,000	12,000,000
(b) Central Depository Bangladesh Limited (5,711,804 Ordinary Shares of Tk. 10/- each)	<u>15,694,430</u>	<u>15,694,430</u>
Non-Convertible Zero Coupon Bonds:	1,112,496,487	1,478,681,650
(c) Envoy Textiles Ltd. (4 Bonds)	5,440,078	10,907,299
(d) Brac Bank Ltd. (400 Bonds)	402,509,850	402,509,850
(e) LankaBangla Finance Ltd. (332 Bonds)	283,068,630	360,363,204
(f) Sajida Foundation Ltd. (200 Bonds)	174,380,055	362,989,522
(g) IDLC Finance Ltd. (480 Bonds)	<u>247,097,874</u>	<u>341,911,775</u>
Non-Convertible Subordinated Bonds:	4,600,000,000	3,500,000,000
(h) Mutual Trust Bank Ltd. (260 Bonds)	2,600,000,000	2,000,000,000
(i) Southeast Bank Ltd. (5,000 Bonds)	500,000,000	500,000,000
(j) Islami Bank Bangladesh Ltd. (50 Bonds)	500,000,000	500,000,000
(k) Trust Bank Ltd. (50 Bonds)	500,000,000	500,000,000
(l) Eastern Bank Ltd. (50 Bonds)	<u>500,000,000</u>	<u>-</u>
	<u>Tk. 5,740,190,917</u>	<u>5,006,376,080</u>

6. Consolidated Inventories: Tk. 11,264,559,965		
Raw Materials	4,566,944,193	2,733,109,087
Packing Materials	1,324,796,436	861,675,938
Work-in-Process	582,686,959	446,012,445
Finished Goods	3,325,238,636	2,549,985,110
Spares & Accessories	919,106,407	853,585,219
Goods- in-Transit	<u>545,787,335</u>	<u>769,743,345</u>
	<u>Tk. 11,264,559,965</u>	<u>8,214,111,144</u>

7. Consolidated Trade and Other Receivables: Tk. 3,792,674,332		
Trade Receivables	2,588,399,894	2,159,066,716
Other Receivables (Note - 7.1)	<u>1,204,274,438</u>	<u>1,236,013,746</u>
	<u>Tk. 3,792,674,332</u>	<u>3,395,080,462</u>

7.1 Consolidated Other Receivables: Tk. 1,204,274,438		
Interest Receivable from Fixed Deposit Receipts	901,084,828	1,132,982,469
Interest Receivable from Short Notice Deposit	120,036,676	-
Gain against Zero Coupon Bonds (Receivable)	102,193,943	52,752,862
Interest Receivable from Subordinated Bonds	<u>80,958,991</u>	<u>50,278,415</u>
	<u>Tk. 1,204,274,438</u>	<u>1,236,013,746</u>

	31-Mar-23	30-Jun-22
8. Consolidated Advances, Deposits and Prepayments: Tk. 1,598,098,720		
Advances:	677,562,469	772,908,102
Employees	365,561,277	304,433,010
Land Purchase	18,891,657	14,204,677
Advance Income Tax	-	216,634,226
Suppliers	293,109,534	237,636,189
Deposits:	901,909,014	945,571,753
Value Added Tax	537,162,980	561,863,297
Earnest Money & Security Deposit	320,452,985	374,066,908
Others	44,293,048	9,641,548
Prepayments:	18,627,238	57,558,092
Office Rent	7,601,000	6,132,743
Insurance Premium	11,026,238	51,425,349
Tk.	1,598,098,720	1,776,037,947
9. Consolidated Cash and Cash Equivalents: Tk. 50,490,880,222		
(a) Cash in Hand	7,541,022	5,886,632
(b) Cash at Bank:	20,505,024,313	2,883,870,319
* Current Accounts	689,230,662	752,173,262
* STD & SND Accounts	19,323,633,370	1,811,898,567
* Export Retention Quota Accounts (held in USD)	253,947,466	249,682,906
* Margin Held Accounts (held in USD)	37,091,318	14,162,725
* Dividend Accounts	201,121,497	55,952,858
(c) Fixed Deposit Receipts (FDRs):	29,978,314,887	46,072,741,385
* FDRs held in BDT	27,308,358,059	41,528,858,059
* FDRs held in USD	2,669,956,828	4,543,883,326
Tk.	50,490,880,222	48,962,498,336
10. Consolidated Fair Value Reserve: Tk. 643,775,757		
Opening Balance (Restated)	830,615,740	1,139,626,144
Add: Unrealised Gain/(Loss) on Marketable Securities for the Period/Year (Note - 28)	(207,599,981)	(393,636,776)
Less: Deferred Tax (Expense)/Income	20,759,998	84,626,372
Closing Balance	643,775,757	830,615,740
11. Translation Reserve: Tk. 26,321,808		
Foreign Operation Translation Gain/(Loss):		
Opening Translation Gain/(Loss)	8,998,071	(285,055)
Translation Gain/(Loss) for the Period/Year	17,323,737	9,283,126
Closing Translation Gain/(Loss)	26,321,808	8,998,071
12. Consolidated Retained Earnings: Tk. 97,652,536,141		
Opening Balance	91,607,512,639	78,749,448,779
Add: Net Profit/(Loss) attributable to Equity holders	14,909,533,603	18,176,769,919
Less: Cash Dividend	(8,864,510,100)	(5,318,706,060)
Closing Balance	97,652,536,141	91,607,512,639
13. Non Controlling Interests: Tk. 252,453		
Opening Balance	469,632	500,000
Add: Net Profit/(Loss) attributable to Non Controlling Interest	(217,180)	(30,368)
Tk.	252,453	469,632
14 Consolidated Long Term Loan: Tk. 1,471,952,125		
a) Standard Chartered Bank, Kenya	371,952,125	294,710,262
b) Standard Chartered Bank, Bangladesh	1,100,000,000	1,400,000,000
Tk.	1,471,952,125	1,694,710,262
15. Consolidated Deferred Tax Liabilities: Tk. 1,149,048,071		
Deferred Tax - Property, Plant and Equipment (Note-15.1)	1,077,517,431	1,086,449,652
Deferred Tax - FVOCI Financial Assets (Note-15.2)	71,530,640	92,290,638
Tk.	1,149,048,071	1,178,740,290
15.1 Deferred Tax - Property, Plant and Equipment: Tk. 1,077,517,431		
Property, plant and equipment (Carrying Amount)	14,902,621,781	13,902,912,754
Property, plant and equipment excluding (Tax Base)	10,113,655,419	9,074,247,632
Taxable/(Deductible) Temporary Difference	4,788,966,362	4,828,665,122
Tax Rate	22.50%	22.50%
Deferred Tax Liabilities as on March 31, 2023	1,077,517,431	1,086,449,652
Deferred Tax Liabilities as on June 30, 2022	1,086,449,652	1,097,936,007
Current Period's Deferred Tax Expense/(Income)	(8,932,221)	(11,486,354)
Tk.	(8,932,221)	(11,486,354)

* Property, plant and equipment is excluding Lands, PPE in transit and Under constructions.

	31-Mar-23	30-Jun-22
15.2 Deferred Tax - FVOCI Financial Assets: Tk. 71,530,640		
FVOCI Financial Assets - Carrying Amount	4,432,755,045	4,346,770,865
FVOCI Financial Assets - Tax Base	<u>3,717,448,648</u>	<u>3,423,864,487</u>
Taxable/(Deductible) Temporary Difference	715,306,397	922,906,378
Tax Rate	10.00%	10.00%
Deferred Tax Liabilities as on March 31, 2023	71,530,640	92,290,638
Deferred Tax Liabilities as on June 30, 2022	<u>92,290,638</u>	<u>176,917,010</u>
Current Period's Deferred Tax Expense/(Income)	Tk. <u><u>(20,759,998)</u></u>	<u><u>(84,626,372)</u></u>
16. Consolidated Long Term Loan - Current Portion: Tk. 440,950,067		
a) Standard Chartered Bank, Kenya	40,950,067	-
b) Standard Chartered Bank, Bangladesh	<u>400,000,000</u>	<u>200,000,000</u>
Tk.	<u><u>440,950,067</u></u>	<u><u>200,000,000</u></u>
17. Consolidated Other Payables: Tk. 2,222,749,171		
Sundry Creditors	559,226,679	501,619,259
Income Tax (Deduction at Source)	14,864,156	16,825,193
Retention Money	14,634,711	8,749,849
Unearned Revenue	141,515,069	-
Dividend Payable	76,733,926	-
Workers' Profit Participation Fund and Welfare Fund	1,382,817,079	1,051,227,994
Interest Payable	<u>32,957,551</u>	<u>25,460,168</u>
Tk.	<u><u>2,222,749,171</u></u>	<u><u>1,603,882,464</u></u>
18. Consolidated Current Tax Liabilities: Tk. 1,361,966,072		
Opening balance	911,504,873	572,675,072
Provision made for the Period/Year	4,029,355,145	4,618,549,626
Tax Paid (Including Advance Income Tax) during the Period	<u>(3,578,893,945)</u>	<u>(4,279,719,825)</u>
Tk.	<u><u>1,361,966,072</u></u>	<u><u>911,504,873</u></u>
19. Consolidated Accrued Expenses: Tk. 180,130,518		
Accrued Expenses	180,130,518	179,997,107
Audit Fees	-	805,000
Tk.	<u><u>180,130,518</u></u>	<u><u>180,802,107</u></u>
	2022-2023	2021-2022
	(Jul'22 - Mar'23)	(Jul'21 - Mar'22)
20. Consolidated Gross Revenue: Tk. 55,858,392,389		
Revenue from Local Sales	54,271,143,552	49,485,461,279
Revenue from Export Sales - Equivalent to US \$16,070,999 (Jul'21-Mar'22: US \$ 14,728,640)	<u>1,587,248,837</u>	<u>1,245,737,052</u>
Tk.	<u><u>55,858,392,389</u></u>	<u><u>50,731,198,331</u></u>
21. Consolidated Cost of Goods Sold: Tk. 23,604,696,522		
Raw Materials Consumed (Note - 21.1)	11,002,631,137	9,583,283,301
Packing Materials Consumed (Note - 21.2)	<u>5,212,907,695</u>	<u>4,685,916,113</u>
	16,215,538,832	14,269,199,414
Add: Opening Work-in-Process	446,012,445	415,013,847
Less: Closing Work-in-Process	<u>(580,874,001)</u>	<u>(419,766,145)</u>
TOTAL CONSUMPTION	16,080,677,276	14,264,447,116
Add: Factory Overhead (Note - 21.3)	<u>6,153,363,490</u>	<u>5,188,884,074</u>
COST OF PRODUCTION	22,234,040,766	19,453,331,190
Add: Opening Finished Goods	2,549,985,110	2,118,362,474
Add: Purchase of Finished Goods	2,304,493,286	1,620,895,269
Less: Closing Finished Goods	<u>(3,316,079,808)</u>	<u>(2,039,397,886)</u>
	23,772,439,354	21,153,191,047
Less: Cost of Physician Sample	<u>(167,742,832)</u>	<u>(154,864,172)</u>
Tk.	<u><u>23,604,696,522</u></u>	<u><u>20,998,326,875</u></u>
21.1 Consolidated Raw Materials Consumed: Tk. 11,002,631,137		
Opening Stock as at 01 July 2022	2,707,894,958	2,647,266,800
Purchase during the period	12,829,477,408	9,488,664,629
Closing Stock as at 31 March 2023	<u>(4,534,741,229)</u>	<u>(2,552,648,128)</u>
Tk.	<u><u>11,002,631,137</u></u>	<u><u>9,583,283,301</u></u>
21.2 Consolidated Packing Materials Consumed: Tk. 5,212,907,695		
Opening Stock as at 01 July 2022	856,951,586	829,398,759
Purchase during the period	5,674,427,326	4,684,067,449
Closing Stock as at 31 March 2023	<u>(1,318,471,217)</u>	<u>(827,550,095)</u>
Tk.	<u><u>5,212,907,695</u></u>	<u><u>4,685,916,113</u></u>

	2022-2023 (Jul'22 - Mar'23)	2021-2022 (Jul'21 - Mar'22)
21.3 Consolidated Factory Overhead: Tk. 6,153,363,490		
Salaries, Allowances & Wages	2,005,226,537	1,727,445,354
Contribution to Provident Fund	43,507,310	37,521,389
Factory Employee Free Lunch	107,167,085	95,791,221
Factory Staff Uniform	89,385,851	82,319,290
Travelling & Conveyance	28,533,066	24,179,434
Printing & Stationery	69,044,510	60,783,417
Postage, Telephone & Fax	6,062,520	5,941,098
Repairs & Maintenance	768,240,492	741,702,079
Laboratory Consumable Stores	379,330,000	314,868,661
Fuel, Petrol, Light Diesel etc.	112,432,128	84,880,706
Electricity, Gas & Water	626,136,024	503,817,338
Rental Expenses	1,144,975	959,540
Municipal & Other Taxes	18,373,199	12,052,394
Insurance Premium	20,049,784	16,503,882
Factory Sanitation Expenses	99,379,343	85,539,604
Depreciation	1,418,255,755	1,130,840,838
Security Services	45,913,727	55,260,468
Research and Development	199,075,827	149,150,546
Software & Hardware Support & VSAT Services	55,658,747	44,880,117
Toll Charges	58,683,144	13,188,282
Other Expenses	1,763,466	1,258,416
Tk.	6,153,363,490	5,188,884,074
22. Consolidated Selling and Distribution Expenses: Tk. 8,607,757,558		
Salaries & Allowances	1,179,362,419	1,058,702,146
Contribution to Provident Fund	80,095,963	68,230,380
Travelling & Conveyance	120,242,738	108,750,645
Printing & Stationery	70,883,187	64,748,229
Postage, Telephone, Fax & Telex	55,215,190	50,899,399
Electricity, Gas & Water	24,638,846	21,371,284
Office & Godown Rent	20,927,583	19,064,348
Repairs & Maintenance including Car Maintenance	410,785,166	371,402,942
Govt Taxes & Licence Fees	27,845,623	32,215,184
Field Staff Salaries, Allowances, TA/DA	2,269,883,718	1,854,322,887
Marketing and Sales Promotional Expenses	1,269,775,896	979,213,248
Event, Programs and Conference	285,669,025	219,738,620
Delivery & Packing Expenses	147,855,201	127,695,301
Literature and Publications	100,715,355	77,059,013
Export Expenses	124,677,179	103,994,738
Research and Product Development	11,962,332	9,013,390
Target Incentive to Field Staff	331,668,887	155,898,418
Special Discount	1,528,427,264	1,349,033,460
Security Services	68,629,591	64,344,233
Depreciation	175,213,653	157,836,300
Software & Hardware Support & VSAT Services	51,634,274	41,923,462
Other Expenses	251,648,468	228,394,424
	8,607,757,558	7,163,852,051
23. Consolidated Administrative Expenses: Tk. 1,080,003,166		
Salaries & Allowances	397,844,191	374,095,842
Contribution to Provident Fund	8,771,018	8,916,576
Directors' Remuneration	65,682,500	52,226,667
Travelling & Conveyance	87,557,741	78,465,548
Printing & Stationery	14,592,093	13,320,980
Postage, Telephone & Internet	7,257,691	7,606,061
Electricity, Gas & Water	37,605,615	19,208,373
Tiffin & Refreshment	60,499,134	53,712,008
Repairs & Maintenance	183,834,883	160,726,130
Bank Charges	11,947,297	9,261,860
Insurance Premium	18,529,785	14,371,352
Govt Taxes & Licence Fees	9,944,849	9,471,143
Security Services	35,372,696	29,108,914
Legal Charges	2,986,294	1,666,661
Depreciation	74,089,892	76,085,964
Software & Hardware Support Services	11,315,157	4,309,003
Other Expenses	52,172,329	40,388,463
	1,080,003,166	952,941,545

	2022-2023 (Jul'22 - Mar'23)	2021-2022 (Jul'21 - Mar'22)
24. Consolidated Finance Cost: Tk. 75,922,988		
Interest expense of Square Pharmaceuticals Ltd.	20,287	25,400
Interest on Term Loan of Square Lifesciences Ltd.	67,119,231	-
Interest on Term Loan of Square Pharmaceuticals Kenya EPZ Ltd.	8,783,469	-
	75,922,988	25,400
25. Consolidated Other Operating Income: Tk. 740,675,243		
Rental Income	1,355,664	1,134,941
Sale of Scrap	37,164,158	33,838,534
Foreign Exchange Gain*	661,001,921	75,196,404
Cash Incentive Received against Export	36,401,000	24,326,000
Technology Transfer fees	4,752,500	-
Industrial Awards	-	400,000
	740,675,243	134,895,879
* Unprecedented fluctuation in the forex rate during the reporting period resulted in unusual foreign exchange gain in the reporting period.		
26. Consolidated Other Income: Tk. 2,867,108,338		
Interest from Deposits	2,004,869,627	1,746,073,798
Interest from Short Notice Deposits	316,800,260	183,654,229
Gain on Redemption of Zero Coupon Bond	74,730,365	26,810,269
Interest from Subordinate Bonds	229,821,198	184,022,918
Dividend Income	156,508,572	58,885,730
Gain on Marketable Securities (Realized)	84,378,316	248,542,913
	2,867,108,338	2,447,989,855
27. Consolidated Income Tax Expense: Tk. 4,020,422,924		
Current Tax Expense	4,029,355,145	3,638,128,933
Deferred Tax Expense / (Income)	(8,932,221)	(31,102,145)
	4,020,422,924	3,607,026,788
28. Profit from Associate Undertakings: Tk. 1,460,477,500		
Square Textiles Ltd.	354,148,391	613,765,057
Square Fashions Ltd.	954,657,791	705,845,280
Square Hospitals Ltd.	151,671,318	136,540,955
	1,460,477,500	1,456,151,292
29. Consolidated Unrealised Gain/(Loss) on FVOCI Financial Assets: Tk. (186,839,983)		
Closing Unrealised Gain/(Loss)	715,306,397	1,146,579,821
Less: Opening Unrealised Gain/(Loss)	922,906,378	1,316,543,154
	(207,599,981)	(169,963,333)
Related Tax	20,759,998	62,259,028
Net Unrealised Gain/(Loss) on FVOCI Financial Assets	Tk. (186,839,983)	(107,704,305)
30. Consolidated Net Asset Value (NAV) per Share: Tk. 123.33		
Equity attributable to the Ordinary Shareholders	109,328,487,006	103,452,979,750
Number of Shares outstanding during the Period/Year	886,451,010	886,451,010
Net Asset Value (NAV) per Share	123.33	116.70
31. Consolidated Earnings per Share (EPS): Tk. 16.82		
Net Profit after Tax attributable to Shareholders	14,909,316,424	14,210,533,807
Number of Shares outstanding during the Period	886,451,010	886,451,010
Earnings per Share (EPS)	16.82	16.03
** Increase in Sales Revenue and proficient usages of materials led to increased gross profit for the reporting period. Prudent investment decisions aided further in increased Net Operating Profit.		
32. Consolidated Net Operating Cash Flow (NOCF) per Share: Tk. 10.95		
Net Cash Generated from Operating Activities	9,707,310,769	12,292,848,045
Number of Shares outstanding during the Period	886,451,010	886,451,010
Net Operating Cash Flow (NOCF) per Share	10.95	13.87

** Amidst the ongoing complexity in the procurement of raw materials and protracted lead time, the Group has paid its regular suppliers in advance to ensure that supply chain does not face any disruption. This precautionary measure has resulted in a reduced net operating cash flow during the reporting period as against the preceding period.

	2022-2023 (Jul'22 - Mar'23)	2021-2022 (Jul'21 - Mar'22)
32.1 Consolidated Reconciliation of Net Profit with Cash Flows Generated from Operating Activities:		
Net Profit after Tax	14,909,316,424	14,210,533,807
Adjustments for:		
Non-Cash Income/Expenses:	(377,633,190)	(194,930,969)
Depreciation	1,667,559,300	1,364,763,102
Exchange Rate Fluctuation	(593,106,506)	(25,281,415)
Profit / (Loss) from Associate Undertakings	(1,460,477,500)	(1,456,151,292)
Cumulative Translation Adjustment	17,323,737	(47,159,219)
Deferred Tax	(8,932,221)	(31,102,145)
Non-Operating Items:	(2,867,108,338)	(2,447,989,855)
Interest from Deposits	(2,004,869,627)	(1,746,073,798)
Interest from Short Notice Deposits	(316,800,260)	(183,654,229)
Interest from Subordinated Bonds	(74,730,365)	(26,810,269)
Gain on Redemption of Zero Coupon Bond	(156,508,572)	(184,022,918)
Dividend Income	(229,821,198)	(58,885,730)
Gain on Marketable Securities (Realized)	(84,378,316)	(248,542,913)
Changes in Working Capital:	(1,957,264,127)	725,235,063
(Increase)/Decrease in Inventories	(3,050,448,821)	178,147,105
(Increase)/Decrease in Trade Receivables	(429,333,178)	(116,782,873)
(Increase)/Decrease in Advances, Deposits and Prepayments	182,626,206	434,477,355
Increase/(Decrease) in Trade Payables	464,024,176	173,720,473
Increase/(Decrease) in Other Payables	426,077,880	426,548,680
Increase/(Decrease) in Current Tax Liabilities	450,461,199	125,861,419
Increase/(Decrease) in Accrued Expenses	(671,589)	(92,737,095)
Net Cash Generated from Operating Activities	9,707,310,769	12,292,848,045
	-	-
33. Consolidated Contingent Liabilities:		
Liabilities for at Sight Letter of Credits as of 31 March 2023:		
a) Square Pharmaceuticals Ltd.: Tk. 5,313,401,934.		
b) Square Lifesciences Ltd.: Tk. 257,305,919.		
b) Square Pharmaceuticals Kenya EPZ Ltd.: Tk. 5,156,788.		
34. Related Party Transactions:		
A. Associates:		
1. Square Textiles Ltd. (46.36% share):		
Opening Balance	-	-
Paid against Dollar Purchase during the Period	3,664,238,300	-
Realized during the Period	(3,664,238,300)	-
Closing Balance	-	-
2. Square Fashions Ltd. (48.63% share):		
Opening Balance	-	-
Paid against Dollar Purchase during the Period	1,557,300,000	135,560,551
Realized during the Period	(1,557,300,000)	(135,560,551)
Closing Balance	-	-
3. Square Hospitals Ltd. (49.94% share):		
Opening Balance	-	-
Paid during the Period	18,324,264	107,229,837
Realized during the Period	(18,324,264)	(107,229,837)
Closing Balance	-	-
B. Subsidiaries of Associates:		
4. Square Denims Ltd. (Subsidiary of Square Fashions Ltd.)		
Opening Balance	-	-
Paid against Dollar Purchase during the Period	197,900,000	-
Realized during the Period	(197,900,000)	-
Closing Balance	-	-
Tk.	-	-
5. Square Apparels Ltd. (Subsidiary of Square Fashions Ltd.)		
Opening Balance	-	-
Paid against Dollar Purchase during the Period	424,800,000	-
Realized during the Period	(424,800,000)	-
Closing Balance	-	-
Tk.	-	-

	2022-2023 (Jul'22 - Mar'23)	2021-2022 (Jul'21 - Mar'22)
C. Others:		
6. Square InformatiX Ltd. (Service Provider):		
Opening Balance	-	-
Paid during the Period	133,322,033	44,149,258
Received/Realized during the Period	(133,322,033)	(44,111,296)
Closing Balance (Receivable)	<u>-</u>	<u>37,962</u>
7. Square Securities Management Ltd. (Port Folio Management):		
Opening Balance	373,879,860	160,545,334
Paid during the Period	132,420,566	692,534,045
Received/Realized during the Period	(341,629,648)	(280,179,539)
Closing Balance (Receivable)	<u>164,670,778</u>	<u>572,899,840</u>
8. Pharma Packages (Pvt.) Ltd. (Supplier):		
Opening Balance	13,692,778	52,600,036
Paid during the Period	379,933,658	328,245,924
Received/Realized during the Period	(356,055,798)	(367,984,573)
Closing Balance (Receivable)	<u>37,570,638</u>	<u>12,861,387</u>
9. AEGIS Services Ltd. (Service Provider):		
Opening Balance	-	-
Paid during the Period	211,550,538	(29,699,190)
Received/Realized during the Period	(211,550,538)	29,699,190
Closing Balance	<u>-</u>	<u>-</u>



SQUARE Pharmaceuticals Ltd.

Statement of Financial Position (Unaudited) As at March 31, 2023

Particulars	Notes	31-Mar-23	30-Jun-22
		Taka	Taka
ASSETS			
Non-Current Assets:		36,142,624,007	34,786,763,350
Property, Plant and Equipment	2	23,344,825,562	22,861,293,922
Investment in Subsidiaries and Associates	3	2,624,852,483	2,572,322,483
Investment in Marketable Securities	4	4,432,755,045	4,346,770,865
Long Term Investment - Others	5	5,740,190,917	5,006,376,080
Current Assets:		67,952,199,483	62,748,423,516
Inventories	6	9,276,755,161	8,176,775,798
Trade and Other Receivables	7	3,808,825,336	3,395,080,462
Advances, Deposits and Prepayments	8	4,445,526,059	2,272,165,190
Cash and Cash Equivalents	9	50,421,092,927	48,904,402,066
TOTAL ASSETS		104,094,823,490	97,535,186,866
EQUITY AND LIABILITIES			
Shareholders' Equity:		98,219,807,450	93,007,355,089
Share Capital		8,864,510,100	8,864,510,100
Share Premium		2,035,465,000	2,035,465,000
General Reserve		105,878,200	105,878,200
Fair Value Reserve	10	643,775,757	830,615,740
Retained Earnings	11	86,570,178,393	81,170,886,049
Non-Current Liabilities:		1,149,048,071	1,178,740,290
Deferred Tax Liabilities	12	1,149,048,071	1,178,740,290
Current Liabilities:		4,725,967,969	3,349,091,486
Trade Payables		921,703,379	636,003,309
Other Payables	13	2,137,920,876	1,491,412,802
Current Tax Liabilities	14	1,361,966,072	911,504,873
Accrued Expenses	15	180,130,518	180,534,472
Unclaimed Dividend		124,247,124	129,636,029
TOTAL LIABILITIES		5,875,016,040	4,527,831,777
TOTAL EQUITY AND LIABILITIES		104,094,823,490	97,535,186,866
Net Assets Value (NAV) per Share	24	110.80	104.92

Sd/-
Samuel S Chowdhury
Chairman

Sd/-
Ratna Patra
Vice Chairman

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Muhammad Zahangir Alam
Chief Financial Officer

Sd/-
Khandaker Habibuzzaman
Company Secretary



SQUARE Pharmaceuticals Ltd.

Statement of Profit or Loss and Other Comprehensive Income (Unaudited) For the 3rd Quarter ended March 31, 2023

Particulars	Notes	Nine Months Results		3rd Quarter Results	
		Jul'22 - Mar'23	Jul'21 - Mar'22	Jan'23 - Mar'23	Jan'22 - Mar'22
		Taka	Taka	Taka	Taka
Gross Revenue	16	55,605,710,362	50,731,198,331	18,098,432,226	16,881,356,230
Less: Value Added Tax		7,679,186,844	7,008,958,984	2,410,605,021	2,231,354,699
Net Revenue		47,926,523,518	43,722,239,347	15,687,827,205	14,650,001,531
Cost of Goods Sold	17	(23,097,081,435)	(20,998,326,875)	(7,733,259,301)	(7,125,580,503)
Gross Profit		24,829,442,083	22,723,912,472	7,954,567,904	7,524,421,028
Operating Expenses:		(9,622,314,858)	(8,089,043,085)	(3,396,023,281)	(2,777,532,203)
Selling and Distribution Expenses	18	(8,601,786,577)	(7,163,852,051)	(3,041,545,098)	(2,443,421,964)
Administrative Expenses	19	(1,020,507,994)	(925,165,634)	(354,467,021)	(334,107,748)
Finance Cost		(20,287)	(25,400)	(11,162)	(2,491)
Other Operating Income	20	804,172,704	134,235,483	248,234,417	45,440,979
Profit from Operations		16,011,299,929	14,769,104,870	4,806,779,040	4,792,329,804
Other Income	21	3,187,136,707	2,630,863,210	1,295,505,395	946,796,650
Profit before WPPF & WF		19,198,436,636	17,399,968,080	6,102,284,435	5,739,126,454
Allocation for WPPF & WF		(914,211,268)	(828,569,909)	(290,584,973)	(273,291,736)
Profit before Tax		18,284,225,367	16,571,398,171	5,811,699,462	5,465,834,718
Income Tax Expenses:	22	(4,020,422,924)	(3,607,026,788)	(1,276,261,168)	(1,198,979,191)
Current Tax (Expense)		(4,029,355,145)	(3,638,128,933)	(1,272,406,925)	(1,202,391,154)
Deferred Tax (Expense)/Income		8,932,221	31,102,145	(3,854,243.00)	3,411,963
Net Profit after Tax		14,263,802,444	12,964,371,383	4,535,438,294	4,266,855,527
Other Comprehensive Income:					
Unrealised Gain/(Loss) on FVOCI Financial Assets:		(186,839,983)	(107,704,305)	37,335,775	(91,766,782)
Unrealised Gain/(Loss) during the Period	23	(207,599,981)	(169,963,333)	41,484,195	(101,963,091)
Deferred Tax (Expense)/Income	12.2	20,759,998	62,259,028	(4,148,420)	10,196,309
Total Comprehensive Income for the Period		14,076,962,461	12,856,667,078	4,572,774,069	4,175,088,745
Earnings Per Share (EPS)	25	16.09	14.63	5.12	4.81

Sd/-
Samuel S Chowdhury
Chairman

Sd/-
Ratna Patra
Vice Chairman

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Muhammad Zahangir Alam
Chief Financial Officer

Sd/-
Khandaker Habibuzzaman
Company Secretary



SQUARE Pharmaceuticals Ltd.

Statement of Changes in Equity (Unaudited) For the 3rd Quarter ended March 31, 2023

(July 2022 - March 2023)

Particulars	Share Capital	Share Premium	General Reserve	Fair Value Reserve	Retained Earnings	Total
	Taka	Taka	Taka	Taka	Taka	Taka
As At 30 June 2022	8,864,510,100	2,035,465,000	105,878,200	830,615,740	81,170,886,049	93,007,355,089
Net Profit after Tax	-	-	-	-	14,263,802,444	14,263,802,444
Other Comprehensive Income (Net of Tax)	-	-	-	(186,839,983)	-	(186,839,983)
Cash Dividend for the year 2021-2022	-	-	-	-	(8,864,510,100)	(8,864,510,100)
As At 31 March 2023	8,864,510,100	2,035,465,000	105,878,200	643,775,757	86,570,178,393	98,219,807,450

Statement of Changes in Equity (Unaudited) For the 3rd Quarter ended March 31, 2022

(July 2021 - March 2022)

Particulars	Share Capital	Share Premium	General Reserve	Fair Value Reserve	Retained Earnings	Total
	Taka	Taka	Taka	Taka	Taka	Taka
As At 30 June 2021	8,864,510,100	2,035,465,000	105,878,200	1,139,626,144	70,072,095,506	82,217,574,950
Net Profit after Tax	-	-	-	-	12,964,371,383	12,964,371,383
Other Comprehensive Income (Net of Tax)	-	-	-	(107,704,305)	-	(107,704,305)
Cash Dividend for the year 2020-2021	-	-	-	-	(5,318,706,060)	(5,318,706,060)
As At 31 March 2022	8,864,510,100	2,035,465,000	105,878,200	1,031,921,839	77,717,760,829	89,755,535,968

Sd/-
Samuel S Chowdhury
Chairman

Sd/-
Ratna Patra
Vice Chairman

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Muhammad Zahangir Alam
Chief Financial Officer

Sd/-
Khandaker Habibuzzaman
Company Secretary



SQUARE Pharmaceuticals Ltd.

Statement of Cash flows (Unaudited) For the 3rd Quarter ended March 31, 2023

Particulars	Notes	Jul'22 - Mar'23	Jul'21 - Mar'22
		Taka	Taka
Cash Flows from Operating Activities:			
Receipts from Customers		55,546,408,466	51,100,026,910
Receipts from Others		229,270,421	62,455,245
Payments to Suppliers		(18,240,490,284)	(15,253,303,307)
Payments for Manufacturing and Operating Expenses		(16,661,432,525)	(12,481,415,295)
Payment of Value Added Tax		(7,679,186,844)	(7,008,958,984)
Cash Generated from Operations		13,194,569,234	16,418,804,568
Interest Paid		(20,287)	(25,400)
Payment of Income Tax		(3,378,893,945)	(3,512,267,514)
Payment to WPPF & WF		(582,622,183)	(937,796,627)
Others		53,633,252	32,955,647
Net Cash Generated from Operating Activities		9,286,666,070	12,001,670,674
Cash Flows from Investing Activities:			
Acquisition of Property, Plant and Equipment		(1,832,174,498)	(2,370,146,183)
Investment in Subsidiaries and Associates		(52,530,000)	(900,000,000)
Long Term Investment - Others		(733,814,837)	(1,514,452,723)
Investment in Marketable Securities		(209,205,845)	412,359,792
Interest Received		2,799,475,827	2,370,971,511
Dividend Received		476,536,941	241,759,084
Net Cash Used in Investing Activities		448,287,587	(1,759,508,519)
Cash Flows from Financing Activities:			
Payment of Dividend		(8,793,165,078)	(5,294,296,721)
Unclaimed Dividend transferred to Capital Market Stabilisation Fund		-	(262,503,350)
Net Cash Used in Financing Activities		(8,793,165,078)	(5,556,800,071)
Net Increase/(Decrease) in Cash and Cash Equivalents		941,788,578	4,685,362,084
Net Effect of Foreign Exchange Fluctuations on Cash and Cash Equivalent		574,902,283	71,780,238
Cash and Cash Equivalents as at 30 June 2022		48,904,402,066	43,354,969,418
Cash and Cash Equivalents as at 31 March 2023		50,421,092,927	48,112,111,740
Net Operating Cash Flow (NOCF) per Share	26	10.48	13.54

Sd/-
Samuel S Chowdhury
Chairman

Sd/-
Ratna Patra
Vice Chairman

Sd/-
Tapan Chowdhury
Managing Director

Sd/-
Muhammad Zahangir Alam
Chief Financial Officer

Sd/-
Khandaker Habibuzzaman
Company Secretary



SQUARE Pharmaceuticals Ltd.

NOTES TO THE INTERIM FINANCIAL STATEMENTS (Unaudited)

For the 3rd Quarter Ended 31 March 2023

1. Basis of Preparation of the Interim Financial Statements:

These Financial Statements ('They') are the Unaudited Interim Financial Statements (here after 'the Interim Financial Statements') of Square Pharmaceuticals Ltd. for the 3rd Quarter ended on March 31, 2023 (here after 'the interim period'). These are prepared in accordance with the International Accounting Standard (IAS) 34 - 'Interim Financial Reporting'. These financial statements should be read in conjunction with the Annual Financial Statements as of June 30, 2022, as these provide an update of previously reported information.

The accounting policies and presentation used are consistent with those used in the Annual Financial Statements, except where mentioned otherwise. Where necessary, the comparative figures have been reclassified or extended from previously reported Interim Financial Statements to take into account any presentational changes made in the Annual Financial Statements or in these Interim Financial Statements.

The preparation of the financial statements requires management to make estimates and assumptions that affect the reported amounts of revenue, expenses, assets, liabilities and disclosure of contingent liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions, which are based on management's best judgement at the date of the Interim Financial Statements, deviate from the actual circumstances, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

The management understands that the business is growing every year which reflects that the assets are performing according to the intention of procurement. The management also assess that the discounted future cash flow from the operation of the assets would be positive if the assets are disposed at the date of financial reporting. But at present, the management has no intention to dispose these assets. Therefore, it is not necessary to record any impairment for the period as per the provisions of IAS-36.

The company operates in industries where significant seasonal or cyclical variations in total sales are not experienced during the reporting

The company has no reportable operating segments as per IFRS-8.

Figures have been rounded off to the nearest Taka.

There is no significant event after the end of the interim period that has to be reflected in these financial statements for the interim period.

2. Property, Plant and Equipment: Tk. 23,344,825,562

Cost:

	31-Mar-23	30-Jun-22
Opening Balance	43,719,669,981	41,570,311,740
Addition during the Period/Year	2,513,307,620	2,408,952,601
	<u>46,232,977,601</u>	<u>43,979,264,341</u>
Sale/Transfer during the Period/Year	-	(259,594,360)
Closing Balance	Tk. <u>46,232,977,601</u>	<u>43,719,669,981</u>

Accumulated Depreciation:

Opening Balance	23,446,178,095	21,793,391,083
Charged during the Period/Year	1,343,955,878	1,835,173,760
	<u>24,790,133,973</u>	<u>23,628,564,843</u>
Sale/Transfer during the Period/Year	-	(182,386,748)
Closing Balance	Tk. <u>24,790,133,973</u>	<u>23,446,178,095</u>

Net Book Value as at 31 March 2023

Property, Plant and Equipment in Transit (Note - 2.1)	573,618,663	521,564,753
Building under Construction (Note - 2.2)	1,328,363,271	2,066,237,283
Written Down Value	Tk. <u>23,344,825,562</u>	<u>22,861,293,922</u>

2.1 Property, Plant and Equipment in Transit: Tk. 573,618,663

Opening Balance	521,564,753	646,809,312
Addition during the Period/Year	632,943,660	1,271,900,734
	<u>1,154,508,413</u>	<u>1,918,710,046</u>
Transfer during the Period/Year	(580,889,750)	(1,397,145,293)
Closing Balance	Tk. <u>573,618,663</u>	<u>521,564,753</u>

2.2 Building under Construction: Tk. 1,328,363,271

Opening Balance	2,066,237,283	1,345,864,835
Addition during the Period/Year	516,448,341	1,280,219,869
	<u>2,582,685,624</u>	<u>2,626,084,704</u>
Transfer during the Period/Year	(1,254,322,353)	(559,847,421)
Closing Balance	Tk. <u>1,328,363,271</u>	<u>2,066,237,283</u>

	31-Mar-23	30-Jun-22
3. Investment in Subsidiaries and Associates: Tk. 2,624,852,483		
Subsidiaries:	2,037,772,688	1,985,242,688
(a) 4,000,000 Ordinary Shares in Square Pharmaceuticals Kenya EPZ Ltd.	332,000,000	332,000,000
(b) Share Money Deposit in Square Pharmaceuticals Kenya EPZ Ltd.	653,742,688	653,742,688
(c) 9,995,000 Ordinary Shares of Tk. 100/- each in Square Lifesciences Ltd.	999,500,000	999,500,000
(d) Share Money Deposit in Samson Pharma Inc., The Philippines	52,530,000	-
Associates:	587,079,795	587,079,795
(a) Square Textiles Ltd. (91,436,677 Ordinary Shares of Tk. 10/- each including Bonus Shares)	225,129,795	225,129,795
(b) Square Hospitals Ltd. (199,750 Ordinary Shares of Tk. 1,000/- each plus Share Premium)	210,750,000	210,750,000
(c) Square Fashions Ltd. (462,000 Ordinary Shares of Tk. 100/- each plus Share Premium)	151,200,000	151,200,000
Tk.	2,624,852,483	2,572,322,483

4. Investment in Marketable Securities: Tk. 4,432,755,045

Particulars	2022-2023 (Jul'22-Mar'23)		2021-2022 (Jul'21-Jun'22)	
	Cost	Market Value	Cost	Market Value
Opening Balance	3,423,864,487	4,346,770,865	3,307,788,552	4,624,331,706
Addition during the Period/Year	341,626,411	218,404,746	627,115,212	562,894,183
Sold during the Period/Year	(48,042,250)	(132,420,566)	(511,039,277)	(840,455,024)
Closing Balance	3,717,448,648	4,432,755,045	3,423,864,487	4,346,770,865

5. Long Term Investment - Others: Tk. 5,740,190,917

Ordinary Shares (Unquoted):	27,694,430	27,694,430
(a) United Hospital Ltd. (120,000 Ordinary Shares of Tk.100/- each)	12,000,000	12,000,000
(b) Central Depository Bangladesh Limited (5,711,804 Ordinary Shares of Tk. 10/- each)	15,694,430	15,694,430
Non-Convertible Zero Coupon Bonds:	1,112,496,487	1,478,681,650
(c) Envoy Textiles Ltd. (4 Bonds)	5,440,078	10,907,299
(d) Brac Bank Ltd. (400 Bonds)	402,509,850	402,509,850
(e) LankaBangla Finance Ltd. (332 Bonds)	283,068,630	360,363,204
(f) Sajida Foundation Ltd. (200 Bonds)	174,380,055	362,989,522
(g) IDLC Finance Ltd. (480 Bonds)	247,097,874	341,911,775
Non-Convertible Subordinated Bonds:	4,600,000,000	3,500,000,000
(h) Mutual Trust Bank Ltd. (260 Bonds)	2,600,000,000	2,000,000,000
(i) Southeast Bank Ltd. (5,000 Bonds)	500,000,000	500,000,000
(j) Islami Bank Bangladesh Ltd. (50 Bonds)	500,000,000	500,000,000
(k) Trust Bank Ltd. (50 Bonds)	500,000,000	500,000,000
(l) Eastern Bank Ltd. (50 Bonds)	500,000,000	-
Tk.	5,740,190,917	5,006,376,080

6. Inventories: Tk. 9,276,755,161

Raw Materials	3,319,047,281	2,707,894,958
Packing Materials	1,016,424,843	856,951,586
Work-in-Process	475,330,119	446,012,445
Finished Goods	3,020,048,155	2,549,985,110
Spares & Accessories	900,117,428	846,188,354
Goods- in-Transit	545,787,335	769,743,345
Tk.	9,276,755,161	8,176,775,798

7. Trade and Other Receivables: Tk. 3,808,825,336

Trade Receivables	2,604,550,898	2,159,066,716
Other Receivables (Note-7.1)	1,204,274,438	1,236,013,746
Tk.	3,808,825,336	3,395,080,462

7.1 Other Receivables: Tk. 1,204,274,438

Interest Receivable from Fixed Deposit Receipts	901,084,828	1,132,982,469
Interest Receivable from Short Notice Deposit	120,036,676	-
Gain against Zero Coupon Bonds (Receivable)	102,193,943	52,752,862
Interest Receivable from Subordinated Bonds	80,958,991	50,278,415
Tk.	1,204,274,438	1,236,013,746

31-Mar-23**30-Jun-22****8. Advances, Deposits and Prepayments: Tk. 4,445,526,059****Advances:**

Employees	365,561,277	304,433,010
Land Purchase	18,891,657	14,204,677
Advance Income Tax	-	200,000,000
Suppliers	3,594,620,486	846,383,507

Deposits:

Value Added Tax	87,288,838	473,471,125
Earnest Money & Security Deposit	317,378,026	371,011,277
Others	44,293,048	9,641,548

Prepayments:

Office Rent	7,601,000	6,132,743
Insurance Premium	9,891,727	46,887,303

Tk. 4,445,526,059 2,272,165,190**9. Cash and Cash Equivalents: Tk. 50,421,092,927**

(a) Cash in Hand	7,339,639	5,686,111
(b) Cash at Bank:	20,435,438,401	2,825,974,570
* Current Accounts	672,174,750	693,577,697
* STD & SND Accounts	19,271,103,370	1,812,598,384
* Export Retention Quota Accounts (held in USD)	253,947,466	249,682,906
* Margin Held Accounts (held in USD)	37,091,318	14,162,725
* Dividend Accounts	201,121,497	55,952,858
(c) Fixed Deposit Receipts (FDRs):	29,978,314,887	46,072,741,385
* FDRs held in BDT	27,308,358,059	41,528,858,059
* FDRs held in USD	2,669,956,828	4,543,883,326
Tk.	50,421,092,927	48,904,402,066

10. Fair Value Reserve: Tk. 643,775,757

Opening Balance	830,615,740	1,139,626,144
Add: Unrealised Gain/(Loss) on Marketable Securities for the Period/Year (Note - 23)	(207,599,981)	(393,636,776)
Less: Deferred tax (Expense)/Income (Note - 12.2)	20,759,998	84,626,372
Closing Balance	643,775,757	830,615,740

11. Retained Earnings: Tk. 86,570,178,393

Opening Balance	81,170,886,049	70,072,095,506
Add: Net Profit/(Loss) for the Period/Year	14,263,802,444	16,417,496,603
Less: Cash Dividend	(8,864,510,100)	(5,318,706,060)
Closing Balance	86,570,178,393	81,170,886,049

12. Deferred Tax Liabilities: Tk. 1,149,048,071

Deferred Tax - Property, Plant and Equipment (Note - 12.1)	1,077,517,431	1,086,449,652
Deferred Tax - FVOCI Financial Assets (Note - 12.2)	71,530,640	92,290,638
Tk.	1,149,048,071	1,178,740,290

12.1 Deferred Tax - Property, Plant and Equipment: Tk. 1,077,517,431

Property, plant and equipment (Carrying Amount)	14,902,621,781	13,902,912,754
Property, plant and equipment (Tax Base)	10,113,655,419	9,074,247,632
Taxable/(Deductible) Temporary Difference	4,788,966,362	4,828,665,122
Tax Rate	22.50%	22.50%
Deferred Tax Liabilities as on March 31, 2023	1,077,517,431	1,086,449,652
Deferred Tax Liabilities as on June 30, 2022	1,086,449,652	1,097,936,007
Current Period's Deferred Tax Expense/(Income)	(8,932,221)	(11,486,354)

* Property, plant and equipment exclude Lands, PPE in transit and Under constructions.

12.2 Deferred Tax - FVOCI Financial Assets: Tk. 71,530,640

FVOCI Financial Assets - Carrying Amount	4,432,755,045	4,346,770,865
FVOCI Financial Assets - Tax Base	<u>3,717,448,648</u>	<u>3,423,864,487</u>
Taxable/(Deductible) Temporary Difference	715,306,397	922,906,378
Tax Rate	10.00%	10.00%
Deferred Tax Liabilities as on March 31, 2023	71,530,640	92,290,638
Deferred Tax Liabilities as on June 30, 2022	<u>92,290,638</u>	<u>176,917,010</u>
Current Period's Deferred Tax Expense/(Income)	Tk. <u>(20,759,998)</u>	<u>(84,626,372)</u>

13. Other Payables: Tk. 2,137,920,876

	31-Mar-23	30-Jun-22
Sundry Creditors	507,355,935	414,609,766
Income Tax (Deduction at Source)	14,864,156	16,825,193
Retention Money	14,634,711	8,749,849
Unearned Revenue	141,515,069	-
Dividend Payable	76,733,926	-
Workers' Profit Participation Fund and Welfare Fund (Note - 13.1)	<u>1,382,817,079</u>	<u>1,051,227,994</u>
Tk.	<u>2,137,920,876</u>	<u>1,491,412,802</u>

13.1 Workers' Profit Participation Fund and Welfare Fund: Tk. 1,382,817,079

Opening balance	1,051,227,994	937,796,627
Add: Allocation for the Period/Year	914,211,268	1,051,227,994
Less: Payment made during the Period/Year	<u>(582,622,183)</u>	<u>(937,796,627)</u>
Closing balance	Tk. <u>1,382,817,079</u>	<u>1,051,227,994</u>

14. Current Tax Liabilities: Tk. 1,361,966,072

Opening balance	911,504,873	572,675,072
Provision made for the Period/Year	4,029,355,145	4,618,549,626
Tax Paid (Including Advance Income Tax) during the Period/Year	<u>(3,578,893,945)</u>	<u>(4,279,719,825)</u>
Tk.	<u>1,361,966,072</u>	<u>911,504,873</u>

15. Accrued Expenses: Tk. 180,130,518

Accrued Expenses	180,130,518	179,844,472
Audit Fees	-	690,000
Tk.	<u>180,130,518</u>	<u>180,534,472</u>

16. Gross Revenue: Tk. 55,605,710,362

	2022-2023 (Jul'22 - Mar'23)	2021-2022 (Jul'21 - Mar'22)
Revenue from Local Sales	54,018,461,525	49,485,461,279
Revenue from Export Sales - Equivalent to US \$16,070,999 (Jul'21-Mar'22: US \$ 14,728,640)	<u>1,587,248,837</u>	<u>1,245,737,052</u>
Tk.	<u>55,605,710,362</u>	<u>50,731,198,331</u>

17. Cost of Goods Sold: Tk. 23,097,081,435

Raw Materials Consumed (Note - 17.1)	10,663,377,714	9,583,283,301
Packing Materials Consumed (Note - 17.2)	<u>5,144,741,117</u>	<u>4,685,916,113</u>
	15,808,118,830	14,269,199,414
Add: Opening Work-in-Process	446,012,445	415,013,847
Less: Closing Work-in-Process	<u>(475,330,119)</u>	<u>(419,766,145)</u>
TOTAL CONSUMPTION	15,778,801,156	14,264,447,116
Add: Factory Overhead (Note - 17.3)	<u>5,651,592,870</u>	<u>5,188,884,074</u>
COST OF PRODUCTION	21,430,394,026	19,453,331,190
Add: Opening Finished Goods	2,549,985,110	2,118,362,474
Add: Purchase of Finished Goods	2,304,493,286	1,620,895,269
Less: Closing Finished Goods	<u>(3,020,048,155)</u>	<u>(2,039,397,886)</u>
	23,264,824,267	21,153,191,047
Less: Cost of Physician Sample	<u>(167,742,832)</u>	<u>(154,864,172)</u>
Tk.	<u>23,097,081,435</u>	<u>20,998,326,875</u>

17.1 Raw Materials Consumed: Tk. 10,663,377,714

Opening Stock as at 01 July 2022	2,707,894,958	2,647,266,800
Purchase during the period	11,274,530,037	9,488,664,629
Closing Stock as at 31 March 2023	<u>(3,319,047,281)</u>	<u>(2,552,648,128)</u>
Tk.	<u>10,663,377,714</u>	<u>9,583,283,301</u>

17.2 Packing Materials Consumed: Tk. 5,144,741,117

Opening Stock as at 01 July 2022	856,951,586	829,398,759
Purchase during the period	5,304,214,374	4,684,067,449
Closing Stock as at 31 March 2023	<u>(1,016,424,843)</u>	<u>(827,550,095)</u>
Tk.	<u>5,144,741,117</u>	<u>4,685,916,113</u>

2022-2023	2021-2022
(Jul'22 - Mar'23)	(Jul'21 - Mar'22)

17.3 Factory Overhead: Tk. 5,651,592,870

Salaries, Allowances & Wages	1,955,672,856	1,727,445,354
Contribution to Provident Fund	43,507,310	37,521,389
Factory Employee Free Lunch	106,971,286	95,791,221
Factory Staff Uniform	86,785,691	82,319,290
Travelling & Conveyance	27,289,298	24,179,434
Printing & Stationery	65,663,329	60,783,417
Postage, Telephone & Fax	6,061,520	5,941,098
Repairs & Maintenance	744,951,353	741,702,079
Laboratory Consumable Stores	362,255,999	314,868,661
Fuel, Petrol, Light Diesel etc.	108,129,930	84,880,706
Electricity, Gas & Water	558,852,712	503,817,338
Rental Expenses	1,144,975	959,540
Municipal & Other Taxes	17,809,819	12,052,394
Insurance Premium	17,695,206	16,503,882
Factory Sanitation Expenses	97,941,000	85,539,604
Depreciation	1,094,652,333	1,130,840,838
Security Services	44,857,234	55,260,468
Research and Development	196,081,250	149,150,546
Software & Hardware Support & VSAT Services	55,589,159	44,880,117
Toll Charges	58,683,144	13,188,282
Other Expenses	997,466	1,258,416
Tk.	<u>5,651,592,870</u>	<u>5,188,884,074</u>

18. Selling and Distribution Expenses: Tk. 8,601,786,577

Salaries & Allowances	1,179,362,419	1,058,702,146
Contribution to Provident Fund	80,095,963	68,230,380
Travelling & Conveyance	120,242,738	108,750,645
Printing & Stationery	70,883,187	64,748,229
Postage, Telephone, Fax & Telex	55,215,190	50,899,399
Electricity, Gas & Water	24,638,846	21,371,284
Office & Godown Rent	20,927,583	19,064,348
Repairs & Maintenance including Car Maintenance	410,785,166	371,402,942
Govt Taxes & Licence Fees	27,845,623	32,215,184
Field Staff Salaries, Allowances, TA/DA	2,269,883,718	1,854,322,887
Marketing and Sales Promotional Expenses	1,269,775,896	979,213,248
Event, Programs and Conference	285,669,025	219,738,620
Delivery & Packing Expenses	147,855,201	127,695,301
Literature and Publications	100,715,355	77,059,013
Export Expenses	124,677,179	103,994,738
Research and Product Development	11,962,332	9,013,390
Target Incentive to Field Staff	331,668,887	155,898,418
Special Discount	1,522,456,283	1,349,033,460
Security Services	68,629,591	64,344,233
Depreciation	175,213,653	157,836,300
Software & Hardware Support & VSAT Services	51,634,274	41,923,462
Other Expenses	251,648,468	228,394,424
Tk.	<u>8,601,786,577</u>	<u>7,163,852,051</u>

19. Administrative Expenses: Tk. 1,020,507,994

Salaries & Allowances	376,672,908	360,788,724
Contribution to Provident Fund	8,771,018	8,916,576
Directors' Remuneration	65,682,500	52,226,667
Travelling & Conveyance	87,557,741	78,465,548
Printing & Stationery	14,523,693	13,320,980
Postage, Telephone & Internet	7,257,691	7,606,061
Electricity, Gas & Water	18,276,433	16,105,581
Tiffin & Refreshment	60,499,134	53,712,008
Repairs & Maintenance	176,746,169	157,672,843
Bank Charges	11,466,273	8,677,282
Insurance Premium	15,923,332	12,206,823
Govt Taxes & Licence Fees	9,101,179	8,199,307
Security Services	35,372,696	29,108,914
Legal Charges	1,288,267	1,197,000
Depreciation	74,089,892	76,085,964
Software & Hardware Support Services	11,315,157	4,082,753
Other Expenses	45,963,911	36,792,603
Tk.	1,020,507,994	925,165,634

2022-2023	2021-2022
(Jul'22 - Mar'23)	(Jul'21 - Mar'22)

20. Other Operating Income: Tk. 804,172,704

Rental Income	10,955,664	1,134,941
Sale of Scrap	37,164,158	33,838,534
Foreign Exchange Gain*	660,121,435	74,536,008
Cash Incentive Received against Export	36,401,000	24,326,000
Commission Received	54,777,947	-
Technology Transfer fees	4,752,500	-
Industrial Awards	-	400,000
Tk.	804,172,704	134,235,483

* Unprecedented fluctuation in the forex rate during the reporting period resulted in unusual foreign exchange gain in the reporting period.

21. Other Income: Tk. 3,187,136,707

Interest from Deposits	2,004,869,627	1,746,073,798
Interest from Short Notice Deposits	316,800,260	183,654,229
Gain on Redemption of Zero Coupon Bond	74,730,365	26,810,269
Interest from Subordinate Bonds	229,821,198	184,022,918
Dividend Income	476,536,941	241,759,084
Gain on Marketable Securities (Realized)	84,378,316	248,542,913
Tk.	3,187,136,707	2,630,863,210

22. Income Tax Expense: Tk. 4,020,422,924

Current Tax Expense	4,029,355,145	3,638,128,933
Deferred Tax Expense / (Income)	(8,932,221)	(31,102,145)
Tk.	4,020,422,924	3,607,026,788

	Jul'2022-Mar'2023		Jul'2021-Mar'2022	
	%	Taka	%	Taka
22.1 Reconciliation of Effective Tax Rate:				
Profit before Tax		18,284,225,367		16,571,398,171
Income Tax using Corporate Tax Rate	22.50%	4,113,950,708	22.50%	3,728,564,589
Effects of:				
Income Exempted from Tax	-0.09%	(16,814,332)	-0.30%	(50,283,064)
Income Taxed at Reduced Rate	-0.42%	(76,713,452)	-0.43%	(71,254,736)
Effective Income Tax	21.99%	4,020,422,924	21.77%	3,607,026,788
Effect of Deferred Tax	0.05%	8,932,221	0.19%	31,102,145
Effective Current Tax	22.04%	4,029,355,145	21.95%	3,638,128,933

23. Unrealised Gain/(Loss) on FVOCI Financial Assets: Tk. (207,599,981)		
Closing Unrealised Gain/(Loss)	715,306,397	1,146,579,821
Less: Opening Unrealised Gain/(Loss)	922,906,378	1,316,543,154
Tk.	(207,599,981)	(169,963,333)

24. Net Asset Value (NAV) per Share: Tk. 110.80		
Equity attributable to the Ordinary Shareholders	98,219,807,450	93,007,355,089
Number of Shares outstanding during the Period/Year	886,451,010	886,451,010
Net Asset Value (NAV) per Share	110.80	104.92

25. Earnings per Share (EPS): Tk. 16.09		
Net Profit after Tax attributable to Shareholders	14,263,802,444	12,964,371,383
Number of Shares outstanding during the Period	886,451,010	886,451,010
Earnings per Share (EPS)	16.09	14.63

** Increase in Sales Revenue and proficient usages of materials led to increased gross profit for the reporting period. Prudent investment decisions aided further in increased Net Operating Profit.

26. Net Operating Cash Flow (NOCF) per Share: Tk. 10.48		
Net Cash Generated from Operating Activities	9,286,666,070	12,001,670,674
Number of Shares outstanding during the Period	886,451,010	886,451,010
Net Operating Cash Flow (NOCF) per Share	10.48	13.54

** Amidst the ongoing complexity in the procurement of raw materials and protracted lead time, the Company has paid its regular suppliers in advance to ensure that supply chain does not face any disruption. This precautionary measure has resulted in a reduced net operating cash flow during the reporting period as against the preceding period.

	2022-2023 (Jul'22 - Mar'23)	2021-2022 (Jul'21 - Mar'22)
26.1 Reconciliation of Net Profit with Cash Flows Generated from Operating Activities:		
Net Profit after Tax	14,263,802,444	12,964,371,383
Adjustments for:		
Non-Cash Income/Expenses:	760,121,374	1,261,880,719
Depreciation	1,343,955,878	1,364,763,102
Exchange Rate Fluctuation	(574,902,283)	(71,780,238)
Deferred Tax	(8,932,221)	(31,102,145)
Non-Operating Items:	(3,187,136,707)	(2,630,863,210)
Interest from Deposits	(2,004,869,627)	(1,746,073,798)
Interest from Short Notice Deposits	(316,800,260)	(183,654,229)
Gain on Redemption of Zero Coupon Bond	(74,730,365)	(26,810,269)
Interest from Subordinate Bonds	(229,821,198)	(184,022,918)
Dividend Income	(476,536,941)	(241,759,084)
Gain on Marketable Securities (Realized)	(84,378,316)	(248,542,913)
Changes in Working Capital:	(2,550,121,042)	406,281,781
(Increase)/Decrease in Inventories	(1,099,979,363)	308,436,795
(Increase)/Decrease in Trade Receivables	(445,484,182)	(116,782,873)
(Increase)/Decrease in Advances, Deposits and Prepayments	(2,168,673,889)	26,371,883
Increase/(Decrease) in Trade Payables	285,700,070	176,342,903
Increase/(Decrease) in Other Payables	428,259,079	(22,318,904)
Increase/(Decrease) in Current Tax Liabilities	450,461,199	125,861,419
Increase/(Decrease) in Accrued Expenses	(403,954)	(91,629,441)
Net Cash Generated from Operating Activities	9,286,666,070	12,001,670,674

27. Contingent Liabilities:

- Liabilities for at Sight Letter of Credits as of 31 March 2023 was Tk. 5,313,401,934.
- The Company issued a Corporate Guarantee in favour of Square Pharmaceuticals Kenya EPZ Ltd. for USD 8.00 Million with due approval of Bangladesh Bank.

28. Related Party Transactions:**28.1 Transaction with Key Management Personnel:**

Amount of compensation paid to Key Management Personnel including Board of Directors during the Period:

Short-Term Employee Benefits	Tk.	335,214,765	289,185,294
Post-Employment Benefits	Tk.	26,356,075	71,927,810
Other Long-Term Benefits		-	-
Termination Benefits		-	-
Share-Based Payment		-	-

28.2 Transaction with Other Related parties:**A. Associates:****1. Square Textiles Ltd. (46.36% share):**

Opening Balance		-	-
Paid against Dollar Purchase during the Period		3,664,238,300	-
Realized during the Period		(3,664,238,300)	-
Closing Balance	Tk.	-	-

2. Square Fashions Ltd. (48.63% share):

Opening Balance		-	-
Paid against Dollar Purchase during the Period		1,557,300,000	135,560,551
Realized during the Period		(1,557,300,000)	(135,560,551)
Closing Balance	Tk.	-	-

3. Square Hospitals Ltd. (49.94% share):

Opening Balance		-	-
Paid during the Period		18,324,264	107,229,837
Realized during the Period		(18,324,264)	(107,229,837)
Closing Balance	Tk.	-	-

B. Subsidiaries:**4. Square Lifesciences Ltd. (99.95% share):**

Opening Balance		653,757,206	-
Addition during the Period		2,996,456,572	2,963,185,168
Realized during the Period		(299,575,046)	(2,470,004,050)
Closing Balance (Receivable)	Tk.	3,350,638,731	493,181,118

2022-2023 (Jul'22 - Mar'23)	2021-2022 (Jul'21 - Mar'22)
---------------------------------------	---------------------------------------

C. Subsidiaries of Associates:**5. Square Denims Ltd. (Subsidiary of Square Fashions Ltd.)**

Opening Balance		-	-
Paid against Dollar Purchase during the Period		197,900,000	-
Realized during the Period		(197,900,000)	-
Closing Balance	Tk.	-	-

6. Square Apparels Ltd. (Subsidiary of Square Fashions Ltd.)

Opening Balance		-	-
Paid against Dollar Purchase during the Period		424,800,000	-
Realized during the Period		(424,800,000)	-
Closing Balance	Tk.	-	-

D. Others:**7. Square InformatiX Ltd. (Service Provider):**

Opening Balance		-	-
Paid during the Period		133,322,033	44,149,258
Realized during the Period		(133,322,033)	(44,111,296)
Closing Balance (Receivable)	Tk.	-	37,962

8. Square Securities Management Ltd. (Portfolio Manager):

Opening Balance	373,879,860	160,545,334
Paid during the Period	132,420,566	692,534,045
Realized during the Period	(341,629,648)	(280,179,539)
Closing Balance (Receivable)	Tk. 164,670,778	572,899,840

9. Pharma Packages (Pvt.) Ltd. (Supplier):

Opening Balance	13,692,778	52,600,036
Paid during the Period	379,933,658	328,245,924
Realized during the Period	(356,055,798)	(367,984,573)
Closing Balance (Receivable)	Tk. 37,570,638	12,861,387

10. AEGIS Services Ltd. (Service Provider):

Opening Balance	-	-
Paid during the Period	211,550,538	(29,699,190)
Realized during the Period	(211,550,538)	29,699,190
Closing Balance	Tk. -	-